Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study

作者：Chang Min Lee, Moon‐Won Yoo, Young‐Gil Son, Sung Jin Oh, Jong-Han Kim, Hyoung‐Il Kim, Joong‐Min Park, Hoon Hur, Ye Seob Jee, Sun-Hwi Hwang, Sung‐Ho Jin, Sang Eok Lee, Ji‐Ho Park, Kyung Won Seo, Sung Soo Park, Chang Hyun Kim, In Ho Jeong, Han Hong Lee, Sung Il Choi, Sang Il Lee, Chan Young Kim, In-Hwan Kim, Myoung Won Son, Kyung Ho Pak, Sung Soo Kim, Moon-Soo Lee, Jae-Seok Min · 发表于：Journal of the Korean Gastric Cancer Association · 年份：2020 · DOI：10.5230/jgc.2020.20.e13 · 被引用次数：14 · 研究领域：Gastric Cancer Management and Outcomes、Esophageal Cancer Research and Treatment、Cholangiocarcinoma and Gallbladder Cancer Studies

PURPOSE: To compare long-term disease-free survival (DFS) between patients receiving tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (CAPOX) adjuvant chemotherapy (AC) for gastric cancer (GC). MATERIALS AND METHODS: This retrospective multicenter observational study enrolled 983 patients who underwent curative gastrectomy with consecutive AC with S-1 or CAPOX for stage II or III GC at 27 hospitals in Korea between February 2012 and December 2013. We conducted propensity score matching to reduce selection bias. Long-term oncologic outcomes, including DFS rate over 5 years (over-5yr DFS), were analyzed postoperatively. RESULTS: The median and longest follow-up period were 59.0 and 87.6 months, respectively. DFS rate did not differ between patients who received S-1 and CAPOX for pathologic stage II (P=0.677) and stage III (P=0.899) GC. Moreover, hazard ratio (HR) for recurrence did not differ significantly between S-1 and CAPOX (reference) in stage II (HR, 1.846; 95% confidence interval [CI], 0.693-4.919; P=0.220) and stage III (HR, 0.942; 95% CI, 0.664-1.337; P=0.738) GC. After adjustment for significance in multivariate analysis, pT (4 vs. 1) (HR, 11.667; 95% CI, 1.595-85.351; P=0.016), pN stage (0 vs. 3) (HR, 2.788; 95% CI, 1.502-5.174; P=0.001), and completion of planned chemotherapy (HR, 2.213; 95% CI, 1.618-3.028; P<0.001) were determined as independent prognostic factors for DFS. CONCLUSIONS: S-1 and CAPOX AC regimens did not show significant difference ...